Teva Secures Dual Denosumab Biosimilar Approvals, Boosting European Bone‑Health Market Share
Teva secures EU approvals for two denosumab biosimilars, PONLIMSI and DEGEVMA, expanding its bone‑health portfolio and boosting market share prospects.
- Teva Pharmaceutical Industries Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read